Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer [0.03%]
新型ALK/ROS1抑制剂Iruplinalkib(WX-0593)在非小细胞肺癌克唑替尼耐药的临床前模型中显示出疗效
Yingying Yang,Qingmei Zheng,Xinmei Wang et al.
Yingying Yang et al.
Despite remarkable initial responses of anaplastic lymphoma kinase (ALK) inhibitors in ALK-positive non-small cell lung cancer (NSCLC) patients, cancers eventually develop resistance within one to two years. This study aimed to compare the ...
SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC [0.03%]
SLIT突变可能是预测非小细胞肺癌免疫治疗疗效的生物标志物
Tong Zhou,Huan Yi,Chan Zhu et al.
Tong Zhou et al.
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments [0.03%]
肺癌患者不同抗肿瘤治疗后B7-H3的表达分布及其临床意义免疫组化分析
Shota Omori,Koji Muramatsu,Takuya Kawata et al.
Shota Omori et al.
B7 homolog 3 protein (B7-H3), an immune checkpoint molecule belonging to the B7 family, has been studied as a target for the development of anti-cancer treatment; however, changes in B7-H3 expression during the clinical course remain unknow...
Antoine Chartouni,Antoine Mouawad,Marc Boutros et al.
Antoine Chartouni et al.
Glioblastoma multiforme (GBM) is the most common and lethal primary tumor of the central nervous system. What makes it so dreadful is the very low survival rate, despite the existence of a standard treatment plan. An innovative and more eff...
Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome [0.03%]
一例复发/难治性塞扎里综合征患者使用tenalisib和romidepsin联合治疗后长期单药维持的完全反应病例报告
Christopher N Nguyen,Swaminathan P Iyer,Madeleine Duvic et al.
Christopher N Nguyen et al.
Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may be refractory to multiple systemic treatments. These cases can be difficult...
Development of a MET-targeted single-chain antibody fragment as an anti-oncogene targeted therapy for breast cancer [0.03%]
一种以MET为靶点的单链抗体片段的开发及其在乳腺癌抗 oncogene 治疗中的应用研究
Rana Vafaei,Zohreh Khaki,Malihe Salehi et al.
Rana Vafaei et al.
The usage of monoclonal antibodies (mAbs) and antibody fragments, as a matter associated with the biopharmaceutical industry, is increasingly growing. Harmonious with this concept, we designed an exclusive modeled single-chain variable frag...
Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group [0.03%]
阿特珠单抗联合贝伐珠单抗治疗肝细胞癌不良事件对生存的影响：日本红十字会肝病研究组多中心研究
Shintaro Takaki,Masayuki Kurosaki,Nami Mori et al.
Shintaro Takaki et al.
This study aimed to describe the real-world efficacy and safety of the combination therapy of atezolizumab and bevacizumab (Atezo/Bev) for unresectable hepatocellular carcinoma (HCC). This retrospective analysis of a multicenter registry co...
Multicenter Study
Investigational new drugs. 2023 Apr;41(2):340-349. DOI:10.1007/s10637-023-01349-4 2023
Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis [0.03%]
纳武利尤单抗诱导的重症肌无力的临床特点、治疗及转归
Chunjiang Wang,Hanqing Zeng,Weijin Fang et al.
Chunjiang Wang et al.
Background: To investigate the clinical features of nivolumab-induced myasthenia gravis (MG) and provide evidence for the rational use of nivolumab in the clinic. ...
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines [0.03%]
CAR-T细胞的GM-CSF RNA干扰降低多种炎症因子分泌
Siqi Shang,Yunshuo Chen,Xuejiao Yang et al.
Siqi Shang et al.
Chimeric antigen receptor T (CAR-T) cell therapy has become a research hotspot in the field of hematological malignancies. However, CAR-T cell therapy can lead to immunotherapy-associated side effects including cytokine release syndrome and...
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines [0.03%]
zanubrutinib对HER2阳性乳腺癌细胞系的抗肿瘤作用
Hana Dostálová,Radek Jorda,Eva Řezníčková et al.
Hana Dostálová et al.
Small molecule Bruton's tyrosine kinase (BTK) inhibitors have been developed for the treatment of various haemato-oncological diseases, and ibrutinib was approved as the first BTK inhibitor for anticancer therapy in 2013. Previous reports p...